Related Experiment Video
Updated: Aug 13, 2026
A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
Published on: March 1, 2022
Left ventricular hypertrophy in daily dialysis
U Buoncristiani1, R Fagugli, G Ciao
1UO Nefrologia-Dialisi and UO Cardiologia, Azienda Ospedaliera di Perugia, Ospedale Silvestrini, Perugia, Italy.
Insights
Daily hemodialysis significantly improves cardiac hypertrophy in ESRD patients by better controlling blood pressure and anemia. This frequent dialysis schedule helps stop progression and even reverse cardiac hypertrophy toward normal levels.
Area of Science:
- Nephrology
- Cardiology
- Internal Medicine
Background:
- Cardiac hypertrophy is a frequent complication in End-Stage Renal Disease (ESRD) patients and a risk factor for cardiovascular death.
- Conventional dialysis treatments often fail to adequately manage blood pressure, a key factor in cardiac hypertrophy progression.
- ESRD patients undergoing dialysis exhibit higher rates of cardiac hypertrophy.
Purpose of the Study:
- To evaluate the impact of daily hemodialysis on cardiac hypertrophy in uremic patients.
- To assess the efficacy of a more frequent dialysis schedule in managing blood pressure and anemia.
- To determine if daily hemodialysis can halt or reverse cardiac hypertrophy progression.
Main Methods:
- Retrospective and prospective studies were conducted by the research group.
- The study involved uremic patients undergoing a daily hemodialysis schedule (6-7 sessions/week, ≥2 hours per session).
- Key parameters monitored included blood pressure control and achievement of true dry weight.
Main Results:
- Daily hemodialysis demonstrated superiority in controlling blood pressure compared to conventional schedules.
- Improvements in anemia management were observed with the daily hemodialysis regimen.
- Studies confirmed that daily hemodialysis stopped the progression of cardiac hypertrophy and led to its reversion toward normality in uremic patients.
Conclusions:
- Daily hemodialysis is a more physiological and effective treatment for ESRD patients with cardiac hypertrophy.
- Excellent blood pressure control, facilitated by easier achievement of dry weight, is the primary mechanism for reversing cardiac hypertrophy.
- This intensified dialysis schedule offers significant cardiovascular benefits for uremic patients.
Abstract:
Cardiac hypertrophy, a well-known independent risk factor for cardiovascular death, is a very frequent complication in ESRD patients. Its frequency tends to be even higher in dialyzed patients due to the fact that the current dialytic treatments are unable to keep under a satisfactory control the various responsible factors and particularly the blood pressure, which is largely the most important. Daily hemodialysis, a more frequent schedule consisting of 6-7 sessions/week lasting 2 or more hours, has definitely proved its superiority in controlling blood pressure and in improving anemia, and thus has the requisites for positively influencing cardiac hypertrophy. In fact, a series of studies, both retrospective and prospective, performed during the last years by our group, have confirmed that this new, more frequent and thus more physiological schedule, is able not only to stop the progression of the cardiac hypertrophy in uremic patients but also to revert toward the normality, in a relatively short time. This appears to be essentially a consequence of the excellent blood pressure control, which in turn derives from the easier control of the true dry weight, achievable with this type of dialytic treatment.
More Related Videos
Related Concept Videos
01:20Mitral Regurgitation I: Introduction
01:29Heart Failure II: Pathophysiology
01:22Heart Failure VI: Adjunct Therapies
01:30Cardiomyopathy II: Dilated Cardiomyopathy
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
01:24Hemodialysis II: Procedure and Complications